Benefits
LDL oxidation reduction (6-month trial)
A pivotal 6-month trial in 19 healthy subjects at 250 mg/day showed plasma LDL oxidation decreased 20%. Atheroprotective mechanism distinct from cholesterol-lowering — addresses the oxidative-modification step in atherogenesis rather than circulating cholesterol levels themselves.
Type 2 diabetes multi-domain effects
A 12-week trial in 10 type 2 diabetes patients at 300 mg/day showed reductions in total cholesterol, LDL-cholesterol, glycated hemoglobin, immunoreactive glucagon, and body fat composition. Multi-target metabolic effects in a small sample. Sample size limits definitive conclusions but the multi-domain pattern is consistent with AMPK activation.
Metabolic syndrome 12-week trial
A 12-week trial in 50 metabolic syndrome patients at 300 mg/day normalized body weight, BMI, visceral fat, and HDL-cholesterol. Larger sample size than the type 2 diabetes trial; multi-domain metabolic syndrome endpoints showed broad normalization.
Skin lightening and hyperpigmentation
Glabridin shows 16 times more potent tyrosinase inhibition than hydroquinone in vitro. A clinical study in 18 subjects showed a hydroquinone-free formula containing glabridin significantly reduced UV-induced hyperpigmentation versus both negative control and 4% hydroquinone cream. Multiple Asian cosmeceutical research applications.
Anti-atherogenic activity
Glabridin is the most abundant and potent antioxidant among the licorice constituents tested for LDL oxidation inhibition. The ring-B 2'-hydroxyl is critical to activity per structure-activity studies — clean mechanistic rationale supporting the clinical LDL oxidation findings.
Anti-inflammatory effects
NF-κB pathway suppression and reduced inflammatory cytokines in cellular and animal models. Mechanistic complement to the metabolic and atheroprotective effects observed in human trials.
Antimicrobial activity (original discovery)
Glabridin was first isolated during a search for antimicrobial agents in licorice root via bioassay-directed fractionation. The original discovery rationale; antimicrobial applications less explored in clinical research than the metabolic and skin uses.
Mechanism of action
LDL oxidation inhibition (primary atheroprotective mechanism)
Glabridin directly inhibits LDL oxidation — the lipid peroxidation step that initiates foam cell formation in atherogenesis. Ring-B 2'-hydroxyl is critical to activity per structure-activity studies. Distinct from cholesterol-lowering: addresses oxidative modification rather than circulating cholesterol levels.
Tyrosinase inhibition (skin lightening)
16× more potent than hydroquinone in vitro. Tyrosinase is the rate-limiting enzyme in melanin biosynthesis — inhibition reduces UV-induced hyperpigmentation. The clinical-evidence-supported mechanism for the cosmeceutical application.
AMPK activation (metabolic mechanism)
Glabridin activates AMP-activated protein kinase (AMPK) — the central metabolic energy sensor. Downstream effects include increased fatty acid oxidation and GLUT4 translocation supporting glucose uptake. Mechanism for the multi-target metabolic effects in Hattori 2019 and Panda 2017.
NF-κB anti-inflammatory pathway suppression
Suppression of NF-κB signaling reduces inflammatory cytokine production. Anti-inflammatory mechanism complementing the metabolic effects.
Mild estrogen receptor binding (phytoestrogenic)
Mild phytoestrogenic activity via estrogen receptor binding. Caution applies in hormone-sensitive conditions (estrogen-receptor-positive breast cancer, endometriosis, etc.).
Low oral bioavailability (~7.5%) — delivery limitation
Critical pharmacokinetic limitation: oral bioavailability is only about 7.5%. Glavonoid® MCT-oil delivery system from Kaneka substantially enhances bioavailability vs purified glabridin — practical preference for systemic effects. Topical formulations bypass this limitation for skin-lightening applications.
Clinical trials
Carmeli E & — 6-month trial in 19 healthy subjects at 250 mg/day glabridin.
19 healthy subjects
Carmeli E & — 6-month trial in 19 healthy subjects at 250 mg/day glabridin. Plasma LDL oxidation decreased 20%. First clinical demonstration of glabridin-driven LDL oxidation reduction in humans — atheroprotective mechanism distinct from cholesterol-lowering.
12-week trial in 10 type 2 diabetes patients at 300 mg/day.
Clinical population described in trial publication.
12-week trial in 10 type 2 diabetes patients at 300 mg/day. Reduced total cholesterol, LDL-cholesterol, glycated hemoglobin, immunoreactive glucagon, and body fat composition. Multi-target metabolic effects in small sample.
12-week trial in 50 metabolic syndrome patients at 300 mg/day.
Clinical population described in trial publication.
12-week trial in 50 metabolic syndrome patients at 300 mg/day. Normalized body weight, BMI, visceral fat, and HDL-cholesterol. Larger sample size; multi-domain metabolic syndrome endpoints.